Navigation Links
Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies
Date:10/21/2008

Quick glance at the latest new drugs. Pharma Opinions unveils a new site were top notch biotech companies will see their new approved products reviewed and commented.

Costa de Caparica, Portugal (PRWEB) October 21, 2008 -- A new blog review on the most recent approved drugs mainly in the U.S. Pharma Opinions unveils a new site were top notch biotech companies will see their new, approved products reviewed and commented on.

Breakthrough drugs and pharmaceutical companies are reviewed each time an approval is issued by FDA. The site extracts all the 'juicy' information from the companies Press Releases and puts it 'plain and simple' for the general opinion to understand the 'facts and figures' of the reason for the drug to be approved, and why it is such a breakthrough.

There will be also interviews with CEOs and officers of the pharmaceutical companies.

Among the most recent reviewed companies are Generex, Biovail and Cephalon

The blog is owned by Bruno Miguel Espalha, a portuguese 27 year old Pharmacist.

You can find the site at pharmaopinions.blogspot.com.

###

Read the full story at http://www.prweb.com/releases/pharmaceuticalblog/newdrugs/prweb1420944.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
2. Amylin Pharmaceuticals Reports Third Quarter Financial Results
3. New Pharmaceutical Company to Target Alzheimers Disease
4. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
5. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
6. China Pharma Holdings, Inc. Appoints The Ruth Group
7. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
8. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
9. Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME)
10. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
11. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... and online shopping cart. The new website has been designed to provide ... digital components allow customers to access detailed product information, read educational industry content ...
(Date:12/7/2016)... Hole, Massachusetts (PRWEB) , ... December 07, 2016 , ... Kara Dwyer Dodge grew up ... Richard Dwyer, a third-generation fisherman in Scituate, Mass., found a sea turtle entangled in the ... shore, where the turtle became a minor sensation because no one could remember ever seeing ...
(Date:12/6/2016)... Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported ... year ended September 30, 2016. ... , , SQI is ... that develops and commercializes proprietary technologies and products for advanced multiplexed ... of $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... 06, 2016 , ... The Osteoarthritis Research Society International (OARSI) ... (FDA) to consider OA as a serious disease. As an organization of professionals ... of OA patients, many of whom may experience progressive disability and decreased quality ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):